We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Review Redefines the Role of MYC in Carcinogenesis

By Biotechdaily staff writers
Posted on 14 Jul 2004
A recent review article that summarized research on the transcription factor MYC revealed that while the MYC protein binds to about 15% of all genes, it does not always activate the genes to which it binds.

N-MYC is a member of the MYC gene family, which contains at least seven closely related genes (C-MYC, N-MYC, L-MYC, P-MYC, R-MYC, S-MYC and B-MYC). More...
The principle functions of MYC are the induction of proliferation and the inhibition of terminal differentiation in certain cells. The human N-MYC gene spans 6-7 kb of genomic DNA and is located on chromosome 2p24.1. The N-MYC proteins have a molecular weight of 65 and 67 kDa.

The gene that codes for synthesis of the MYC protein is the most overexpressed oncogene found in human cancers. Investigators at the Wistar Institute (Philadelphia, PA, USA; www.wistar.upenn.edu) recently reviewed the status of research on MYC for the July 2004 issue of Nature Reviews Cancer. They found that while MYC binds to as many as 15% of all genes, binding alone does not always activate the gene. This observation calls into question long-held assumptions about MYC's functioning and opens new directions for MYC research.

"Previous studies looked at which genes are bound by MYC, and it turns out to be a great percentage of genes--one out of every six,” said senior author Dr. Steven McMahon, an assistant professor at the Wistar Institute. "Our work has extended what these studies hinted at: contrary to what was believed, MYC does not always turn on the genes to which it binds. The implication is that just figuring out which genes bind to MYC will not be enough to tell us what pathways are being activated in cancer. There must be other factors that play a role in whether MYC activates a gene.”



Related Links:
Wistar Institute

New
Gold Member
Automatic Hematology Analyzer
CF9600
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
LAIR2 Antibody Pair Set
LAIR2 Antibody Pair [Biotin]
New
Repetitive Pipette
VWR® Stepper Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.